Sanofi Suits Can't Survive Omnicare Ruling, 2nd Circ. Says
The Second Circuit on Friday refused to revive a pair of securities class actions against drugmaker Sanofi over the rollout of its multiple sclerosis treatment Lemtrada, saying last year's Omnicare ruling...To view the full article, register now.
Already a subscriber? Click here to view full article